IE
SYRS

Israel Englander’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Israel Englander’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,700
Closed -$68.2K – 6573
2024
Q3 		$68.2K Sell
31,700
-31,314
-50% -$112K ﹤0.01% 5652
2024
Q2 		$325K Sell
63,014
-198,069
-76% -$1.04M ﹤0.01% 4866
2024
Q1 		$1.4M Buy
+261,083
New +$1.81M ﹤0.01% 4028
2023
Q3 		– Sell
-12,825
Closed -$40.4K – 6670
2023
Q2 		$40.4K Sell
12,825
-65,511
-84% -$211K ﹤0.01% 5513
2023
Q1 		$209K Sell
78,336
-13,137
-14% -$50.9K ﹤0.01% 5146
2022
Q4 		$328K Buy
91,473
+21,839
+31% +$94.8K ﹤0.01% 5033
2022
Q3 		$448K Sell
69,634
-26,776
-28% -$218K ﹤0.01% 5057
2022
Q2 		$928K Buy
96,410
+45,228
+88% +$423K ﹤0.01% 4430
2022
Q1 		$609K Buy
51,182
+41,952
+455% +$750K ﹤0.01% 4968
2021
Q4 		$301K Sell
9,230
-22,408
-71% -$907K ﹤0.01% 5538
2021
Q3 		$1.41M Sell
31,638
-24,133
-43% -$1.18M ﹤0.01% 4302
2021
Q2 		$3.04M Buy
55,771
+38,892
+230% +$2.3M ﹤0.01% 3419
2021
Q1 		$1.26M Sell
16,879
-21,148
-56% -$2.2M ﹤0.01% 3993
2020
Q4 		$4.13M Buy
38,027
+22,924
+152% +$2.09M ﹤0.01% 2630
2020
Q3 		$1.33K Sell
15,103
-203
-1% -$23.1K ﹤0.01% 2921
2020
Q2 		$1.63M Buy
+15,306
New +$1.37M ﹤0.01% 2668
2020
Q1 		– Sell
-52,559
Closed -$3.63M – 4626
2019
Q4 		$3.63M Buy
52,559
+50,681
+2,699% +$3.07M ﹤0.01% 2177
2019
Q3 		$194K Buy
+1,878
New +$177K ﹤0.01% 3804
2019
Q2 		– Sell
-6,972
Closed -$637K – 4553
2019
Q1 		$637K Sell
6,972
-2,647
-28% -$184K ﹤0.01% 3120
2018
Q4 		$536K Sell
9,619
-7,666
-44% -$582K ﹤0.01% 2925
2018
Q3 		$2.06M Sell
17,285
-20,262
-54% -$2.35M ﹤0.01% 2415
2018
Q2 		$3.83M Buy
37,547
+21,170
+129% +$2.62M 0.01% 1972
2018
Q1 		$2.13M Buy
+16,377
New +$1.79M ﹤0.01% 2273
2017
Q4 		– Sell
-11,321
Closed -$1.67M – 4137
2017
Q3 		$1.67M Buy
+11,321
New +$2.13M ﹤0.01% 2262
2017
Q2 		– Sell
-1,165
Closed -$186K – 3952
2017
Q1 		$186K Buy
+1,165
New +$142K ﹤0.01% 3229

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Israel Englander's SYRS Position: Q4 2024 in Review

Israel Englander sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 31,700 shares — an estimated $68.2K sold.

Israel Englander first reported a position in SYRS in Q1 2017 and held it in 25 quarters. The position peaked at $4.13M in Q4 2020. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Israel Englander reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Israel Englander sold 31,700 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $68.2K.
  • Israel Englander first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
  • Israel Englander's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.13M in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Millennium Management's 13F filing for Q4 2024, filed 14 Feb 2025.